TARRYTOWN, N.Y., June 8, 2020 /PRNewswire/ -- Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a
change in the format and location of its 2020 Annual Meeting of
Shareholders. In light of the continued public health concerns
regarding the COVID-19 pandemic, and to protect the health of our
shareholders, employees and other attendees, the Annual Meeting
will be held solely by remote communication, in a "virtual-only"
format. Shareholders will no longer have the option to attend the
Annual Meeting in person. The meeting will still be held on
June 12, 2020 at 10:30 a.m., Eastern Time, at the previously
announced date and time.
The meeting will be webcast and can be accessed by shareholders
at www.virtualshareholdermeeting.com/REGN2020. Only shareholders
that log in using the 16-digit control number provided to them
either on their Notice of Internet Availability of Proxy Materials
or, if they received a paper copy of the proxy materials, on the
proxy card or voting instruction form will be able to vote and
submit questions during the Annual Meeting. Regeneron has designed
the format of the Annual Meeting to ensure that shareholders are
afforded similar opportunities to participate as they would at an
in-person meeting, using online tools to ensure shareholder access
As described in the proxy materials for the Annual Meeting,
shareholders are entitled to attend and vote at the Annual Meeting
if they held Regeneron shares as of the close of business on
April 14, 2020, the record date
designated by Regeneron's Board of Directors for the Annual
Meeting. To learn more about accessing and participating in the
virtual meeting, please refer to Regeneron's Notice of Change of
Format and Location filed with the U.S. Securities and Exchange
Commission on June 8, 2020.
About Regeneron Pharmaceuticals, Inc.
Regeneron is a
leading biotechnology company that invents life-transforming
medicines for people with serious diseases. Founded and led for
over 30 years by physician-scientists, Regeneron's unique ability
to repeatedly and consistently translate science into medicine has
led to seven FDA-approved treatments and numerous product
candidates in development, all of which were homegrown in
Regeneron's laboratories. Regeneron's medicines and pipeline are
designed to help patients with eye diseases, allergic and
inflammatory diseases, cancer, cardiovascular and metabolic
diseases, pain, infectious diseases, and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through its proprietary
VelociSuite® technologies, such as
VelocImmune®, which uses unique
genetically-humanized mice to produce optimized fully-human
antibodies and bispecific antibodies, and through ambitious
research initiatives such as the Regeneron Genetics
Center®, which is conducting one of the largest genetics
sequencing efforts in the world.
Tel: +1 (914)
Tel: +1 (914)
SOURCE Regeneron Pharmaceuticals, Inc.